NCT01999868: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT01999868 |
|---|---|
| Title | Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | March 19, 2014 |
| Completion date | Dec. 7, 2017 |
| Required reporting date | Dec. 7, 2018, midnight |
| Actual reporting date | Dec. 4, 2018 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |